Search
Monte Rosa Therapeutics Inc
GLUEAdd to Watchlist
18.310USD
-0.100-0.54%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Monte Rosa Therapeutics Inc is 8.67, ranking 77 out of 389 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 13.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
32.600
Target Price
+78.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Monte Rosa Therapeutics Inc
GLUE
9
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Monte Rosa Therapeutics Inc's expected revenue for the next quarter?
Monte Rosa Therapeutics Inc's expected revenue is 5.52M.
What is Monte Rosa Therapeutics Inc's price target?
Analysts forecast that Monte Rosa Therapeutics Inc's price target is USD 18.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 13.00.
How have Monte Rosa Therapeutics IncGLUE's recent earnings per share performed?
The market expectation was USD -0.45, while Monte Rosa Therapeutics IncGLUE's earnings per share (EPS) for the previous quarter was USD -0.54. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Monte Rosa Therapeutics Inc?
Based on the ratings of Monte Rosa Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
